Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analogues, beta-blocker and CAI
- Conditions
- Glaucoma
- Registration Number
- JPRN-UMIN000006831
- Lead Sponsor
- Hospital, University of the Ryukyus
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Not provided
(1) Patients who have undergone an operation (including laser operation) within 3 months before the study. (2) Patients who have difficulty in measuring intraocular pressure using an applanation tonometer. (3) Patients who have difficulty or are unable to undergo fundoscopy (corneal opacity, severe cataract, etc.). (4) Patients expected to require operation for an eye disease during the study period. (5) Patients with serious renal impairment (nephrotic syndrome, acute renal failure, chronic renal failure, etc.) (6) Patients with hepatic function disorder. (7) Patients with bronchial asthma or its history. (8) Patients with bronchospasm or serious chronic obstructive pulmonary disease. (9) Patients with cardiac failure, sinus bradycardia, atrioventricular block (second and third degrees), or cardiogenic shock. (10) Patients with right cardiac failure due to pulmonary hypertension. (11) Patients with congestive cardiac failure. (12) Patients with diabetic ketoacidosis and/or metabolic acidosis. (13) Patients with poorly controlled diabetes mellitus. (14) Patients with a anamnestic history of hypersensitivity to any ingredients of the investigational product. (15)Patients who has received administration of the adrenocortical steroid agent (Skin local administration other than an eye circumference part is good). (16) During a pregnant woman, the nursing or a patient with possibility becoming pregnant. (17) Patients whom it was judged a doctor not to be suitable as an object of the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method